EYE » Topics » FOR ITS 7 1 / 2 % SENIOR SUBORDINATED NOTES DUE 2017

This excerpt taken from the EYE 8-K filed Feb 25, 2009.

FOR ITS 7 1/2% SENIOR SUBORDINATED NOTES DUE 2017

SANTA ANA, Calif., Feb. 25, 2009 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE] announced today the expiration of the tender offer and consent solicitation (the “Offer”) for its outstanding 7 1/2% Senior Subordinated Notes due 2017 (the “Notes”) (CUSIP No. 00763MAN8, ISIN No. US00763MAN83). The Offer expired at midnight EST on Tuesday, Feb. 24, 2009, (the “Expiration Time”). As of the Expiration Time, $248,250,000 aggregate principal amount of Notes, representing approximately 99.3% of the aggregate principal amount of Notes outstanding, had been validly tendered pursuant to the Offer and not withdrawn. AMO accepted for payment, and will pay for, $248,250,000 aggregate principal amount of Notes today (the “Payment Date”).

Holders who validly tendered their Notes and delivered their related consents prior to the Expiration Time received the Total Consideration of $1,155.00 for each $1,000 principal amount of Notes validly tendered and accepted for payment. In addition, all holders whose Notes were accepted for payment received accrued and unpaid interest up to, but not including, the Payment Date.

In addition, pursuant to the Offer, AMO received consents from holders sufficient to approve the proposed amendments to the indenture governing the Notes. As a result, AMO and the trustee will enter into a supplemental indenture containing the proposed amendments to such indenture.

This press release is for informational purposes only and is not an offer to purchase, a solicitation of an offer to sell or a solicitation of a consent with respect to any of the Notes. The tender offer and the consent solicitation were only made pursuant to the tender offer and the consent solicitation documents, including the Offer to Purchase that AMO distributed to holders of Notes. The tender offer and the consent solicitation were not made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.


This excerpt taken from the EYE 10-K filed Feb 24, 2009.

7  1/2% Senior Subordinated Notes Due 2017

In April 2007, the Company issued $250 million of 7 1/2% Notes due May 1, 2017. Interest on the 7 1/2% Notes is payable on May 1 and November 1 of each year, commencing on November 1, 2007. The 7 1/2% Notes are redeemable at the option of the Company, in whole or in part, at any time on or after May 1, 2012 at various redemption prices, together with accrued and unpaid interest and additional interest, if any, to the redemption date. In addition, at any time on or before May 1, 2010, the Company may, at its option and subject to certain requirements, use the cash proceeds from one or more qualified equity offerings by the Company to redeem up to 35% of the aggregate principal amount of the 7 1/2% Notes issued under the Indenture at a redemption price equal to 107.5% of the principal amount, together with accrued and unpaid interest, if any, thereon to the redemption date.

This excerpt taken from the EYE 10-K filed Mar 3, 2008.

7 1/2% Senior Subordinated Notes Due 2017 (7 1/2% Notes)

In April 2007, the Company issued $250 million of 7 1 /2% Senior Subordinated Notes due May 1, 2017. Interest on the 7 1/2% Notes is payable on May 1 and November 1 of each year, commencing on November 1, 2007. The 7 1/2% Notes are redeemable at the option of the Company, in whole or in part, at any time on or after May 1, 2012 at various redemption prices, together with accrued and unpaid interest and additional interest, if any, to the redemption date. In addition, at any time on or before May 1, 2010, the Company may, at its option and subject to certain requirements, use the cash proceeds from one or more qualified equity offerings by the Company to redeem up to 35% of the aggregate principal amount of the 7 1/2% Notes issued under the Indenture at a redemption price equal to 107.5% of the principal amount, together with accrued and unpaid interest, if any, thereon to the redemption date.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki